What does this research mean for the field?

Long-term treatment with ravulizumab provides a sustained reduction in clinical relapse risk and maintains a consistent safety profile in adults with AQP4-Ab+ neuromyelitis optica spectrum disorder. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To assess the long-term efficacy and safety of ravulizumab in adults with AQP4-Ab+ neuromyelitis optica spectrum disorder.

July 16, 2026Neurology Neuroimmunology & NeuroinflammationOpen Access

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder

View Full Paper

Ask AI

Bookmark

To assess the long-term efficacy and safety of ravulizumab in adults with AQP4-Ab+ neuromyelitis optica spectrum disorder.
Adult patients with AQP4-Ab+ NMOSD received weight-based doses of ravulizumab intravenously.
Follow-up included a primary treatment period of up to 2.5 years and a long-term extension phase.
The primary endpoint was time to first adjudicated on-trial relapse compared to a placebo group from another trial.
Long-term treatment reduced the risk of relapse significantly (< 0.0001).
94.8% of participants reported treatment-emergent adverse events (TEAEs), with 27.6% classified as serious.
Two cases of meningococcal infection were recorded during the primary treatment phase, none in the long-term extension.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates reduced relapse risk in adults with AQP4-Ab+ NMOSD, suggesting strong treatment potential.

Cite This Study

Pittock et al. (2026) studied this question.

synapsesocial.com/papers/6a5874652b46c88ba9ad080d https://doi.org/10.1212/nxi.0000000000200609

View Full Paper

Ask AI

Bookmark

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder

Key Points

Discussion

Implication

Cite This Study

Long-Term Ravulizumab Efficacy and Safety in AQP4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider